GT
GYRE icon

Glenmede Trust’s Gyre Therapeutics GYRE Stock Holding History

Glenmede Trust’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed – – 2699
2015
Q3 		$0 Hold
1
– – ﹤0.01% 2761
2015
Q2 		$1K Hold
1
– – ﹤0.01% 2539
2015
Q1 		$1K Sell
1
-1
-50% -$2.07K ﹤0.01% 2397
2014
Q4 		$3K Hold
2
– – ﹤0.01% 2376
2014
Q3 		$3K Hold
2
– – ﹤0.01% 2315
2014
Q2 		$5K Hold
2
– – ﹤0.01% 2152
2014
Q1 		$5K Hold
2
– – ﹤0.01% 2156
2013
Q4 		$5K Hold
2
– – ﹤0.01% 2120
2013
Q3 		$6K Hold
2
– – ﹤0.01% 2013
2013
Q2 		$5K Buy
+2
New +$7.61K ﹤0.01% 1995

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Glenmede Trust's GYRE Position: Q4 2015 in Review

Glenmede Trust sold out of Gyre Therapeutics (GYRE) in Q4 2015, closing a stake of 1 share.

Glenmede Trust first reported a position in GYRE in Q2 2013 and held it in 10 quarters. The position peaked at $6K in Q3 2013. 35 funds tracked by Wall St. Rank hold GYRE as of Q4 2015.

  • Glenmede Trust reported no remaining Gyre Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Glenmede Trust sold 1 Gyre Therapeutics share in Q4 2015.
  • Glenmede Trust first reported a position in Gyre Therapeutics in Q2 2013 and held it in 10 quarters.
  • Glenmede Trust's Gyre Therapeutics position peaked at $6K in Q3 2013.
  • 35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2015.

Based on Glenmede Trust's 13F filing for Q4 2015, filed 11 Feb 2016.